Compare TGHL & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGHL | GDTC |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | Singapore | Singapore |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 12.4M |
| IPO Year | N/A | 2021 |
| Metric | TGHL | GDTC |
|---|---|---|
| Price | $0.31 | $1.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 21.1K | 9.5K |
| Earning Date | 05-18-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $5.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.73 |
| 52 Week High | $3.80 | $3.68 |
| Indicator | TGHL | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 39.74 | 45.91 |
| Support Level | $0.29 | $0.97 |
| Resistance Level | $0.51 | $1.11 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 10.81 | 45.13 |
The Growhub Ltd operates at the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, It has developed a multi-faceted approach to address industry challenges. its business currently comprises two main divisions, which are the GrowHub Platform and its product trading facilitation offering.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.